August 19, 2009
Gilead Sciences' Executive Vice President Establishes Rule 10b5-1 Stock Trading Plan
FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 19, 2009--
Gilead Sciences, Inc. (Nasdaq:GILD) today announced the establishment of
a new stock trading plan under Rule 10b5-1 of the Securities Exchange
Act of 1934 on August 19, 2009 by Gregg H. Alton, Executive Vice
President, Corporate and Medical Affairs of Gilead. Commencing in
January 2010, Mr. Alton’s plan provides for the exercise and sale of
certain options each month through December 2010.
The transactions under the plan are disclosed publicly through Form 144
and Form 4 filings with the Securities and Exchange Commission. James M.
Denny, Gilead’s lead independent director of the Board, Paul Berg, PhD,
a member of Gilead’s Board of Directors, John C. Martin, PhD, Chairman
and Chief Executive Officer, John F. Milligan, PhD, President and Chief
Operating Officer, Kevin Young, Executive Vice President, Commercial
Operations, and Kristen M. Metza, Senior Vice President, Human
Resources, maintain stock trading plans under Rule 10b5-1, and other
officers and directors of the company may do so in the future.
Rule 10b5-1 allows insiders to adopt written plans for trading
securities in a non-discretionary, pre-scheduled manner in order to
avoid concerns about initiating stock transactions when the insider may
be aware of non-public information. Such plans also allow insiders to
diversify their holdings and to minimize the market effect of stock
sales by spreading them out over time.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Headquartered in Foster City,
California, Gilead has operations in North America, Europe and Australia.
For more information on Gilead Sciences, please visit www.gilead.com
or call the Gilead Public Affairs Department at 1-800-GILEAD-5
(1-800-445-3235).
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Amy
Flood, 650-522-5643 (Media)
www.gilead.com
